- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
Patent holdings for IPC class A61K 31/502
Total number of patents in this class: 1411
10-year publication summary
|
72
|
72
|
88
|
103
|
109
|
131
|
157
|
145
|
162
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| AstraZeneca AB | 2961 |
38 |
| MetrioPharm AG | 46 |
36 |
| F. Hoffmann-La Roche AG | 7942 |
23 |
| Amgen Inc. | 3894 |
19 |
| Novartis AG | 11297 |
16 |
| Rigel Pharmaceuticals, Inc. | 586 |
15 |
| The Regents of the University of California | 19479 |
14 |
| KuDOS Pharmaceuticals Limited | 48 |
14 |
| Mirati Therapeutics, Inc. | 225 |
13 |
| Genentech, Inc. | 3864 |
12 |
| The Johns Hopkins University | 5519 |
12 |
| Dana-Farber Cancer Institute, Inc. | 2531 |
12 |
| Board of Regents, The University of Texas System | 5604 |
11 |
| Daiichi Sankyo Company, Limited | 1863 |
11 |
| Takeda Pharmaceutical Company Limited | 2945 |
10 |
| Jiangsu Hengrui Medicine Co., Ltd. | 760 |
10 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 803 |
10 |
| Bergenbio ASA | 59 |
10 |
| Glaxo Group Limited | 4286 |
9 |
| Bristol-myers Squibb Company | 4886 |
9 |
| Other owners | 1107 |